14th Mar 2019 15:52
LONDON (Alliance News) - Shield Therapeutics PLC on Thursday said its Feraccru patent met the requirements of the European Patent Convention, which will continue to provide protection to Feraccru through to 2032.
Feraccru was created for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease.
The pharmaceutical company said the decision follows a hearing in relation to the opposition that had been filed against the patent by a third party.
Shield Therapeutics shares were trading 4.0% higher on Thursday at 68.64 pence each.
Related Shares:
Shield Thera